Copy to clipboard 
Dymicron announced the successful enrollment and treatment of the first patient in its Triadyme-C Investigational Device Exemption (IDE) clinical trial. This milestone marks the initiation of a U.S. clinical study evaluating the safety and effectiveness of the Triadyme-C cervical artificial disc.
Triadyme–C device features bearing surfaces made from Adymite, Dymicron’s proprietary, medical-grade polycrystalline diamond technology. Adymite is engineered to dramatically reduce wear debris generation compared to conventional implant materials such as titanium, cobalt-chromium, and polyethylene. The result is a device with exceptional hardness, low friction, and long-term articulation performance, optimized for the lifetime demands of spinal motion preservation.
The IDE trial was designed to assess clinical and radiographic outcomes in patients with cervical degenerative disc disease requiring surgical intervention, and will enroll patients across multiple investigational sites in the U.S.
“Enrollment of the first patient in our Triadyme-C IDE trial represents a significant milestone for Dymicron, and underscores years of focused innovation and validation,” said Alan S. Layton, Chief Executive Officer and Chairman of the Board at Dymicron. “This achievement reflects the dedication of our team and clinical partners, and it moves us one step closer to providing U.S. surgeons and patients with a next-generation cervical artificial disc designed to preserve motion while addressing the limitations of existing technologies.”
Source: Dymicron
Dymicron announced the successful enrollment and treatment of the first patient in its Triadyme-C Investigational Device Exemption (IDE) clinical trial. This milestone marks the initiation of a U.S. clinical study evaluating the safety and effectiveness of the Triadyme-C cervical artificial disc.
Triadyme–C device features bearing...
Dymicron announced the successful enrollment and treatment of the first patient in its Triadyme-C Investigational Device Exemption (IDE) clinical trial. This milestone marks the initiation of a U.S. clinical study evaluating the safety and effectiveness of the Triadyme-C cervical artificial disc.
Triadyme–C device features bearing surfaces made from Adymite, Dymicron’s proprietary, medical-grade polycrystalline diamond technology. Adymite is engineered to dramatically reduce wear debris generation compared to conventional implant materials such as titanium, cobalt-chromium, and polyethylene. The result is a device with exceptional hardness, low friction, and long-term articulation performance, optimized for the lifetime demands of spinal motion preservation.
The IDE trial was designed to assess clinical and radiographic outcomes in patients with cervical degenerative disc disease requiring surgical intervention, and will enroll patients across multiple investigational sites in the U.S.
“Enrollment of the first patient in our Triadyme-C IDE trial represents a significant milestone for Dymicron, and underscores years of focused innovation and validation,” said Alan S. Layton, Chief Executive Officer and Chairman of the Board at Dymicron. “This achievement reflects the dedication of our team and clinical partners, and it moves us one step closer to providing U.S. surgeons and patients with a next-generation cervical artificial disc designed to preserve motion while addressing the limitations of existing technologies.”
Source: Dymicron
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
